Literature DB >> 16954517

Prognostic significance of T-cell or cytotoxic molecules phenotype in classical Hodgkin's lymphoma: a clinicopathologic study.

Naoko Asano1, Aya Oshiro, Keitaro Matsuo, Yoshitoyo Kagami, Fumihiro Ishida, Ritsuro Suzuki, Tomohiro Kinoshita, Yoshie Shimoyama, Jun-Ichi Tamaru, Tadashi Yoshino, Kunio Kitamura, Hisashi Fukutani, Yasuo Morishima, Shigeo Nakamura.   

Abstract

PURPOSE: Classical Hodgkin's lymphoma (CHL) is characterized by Hodgkin's and Reed-Sternberg (H-RS) cells, most of which are derived from germinal-center B cells. Nevertheless, one or more markers for T cells and follicular dendritic cells (FDC) may be expressed in a minority of H-RS cells in some CHL patients, although the clinical significance of this remains controversial. The aim of this study was to clarify the association between phenotypic expression and clinical outcome in CHL. PATIENTS AND METHODS: Participants were 324 consecutive CHL patients, comprising 132 patients with nodular sclerosis (NS), 35 patients with NS grade 2 (NS2), and 157 patients with mixed cellularity (MC). We evaluated the presenting features and prognosis of patients on categorization into four phenotypically defined groups: B-cell (CD20+ and/or CD79a+; n = 63), T-cell and/or cytotoxic molecules (CD3+, CD4+, CD8+, CD45RO+, TIA-1+, and/or granzyme B+; n = 27), FDC (CD21+ without B-cell marker; n = 22), and null-cell types (n = 212). Other potential prognostic factors were examined.
RESULTS: The T-cell and/or cytotoxic molecules group showed a significantly poorer prognosis than the other three groups (P < .0001). This finding was seen consistently in multivariate analyses. Morphologic subtyping (NS/NS2/MC) and Epstein-Barr virus positivity were not identified as independent prognostic factors.
CONCLUSION: The presence of T-cell and/or cytotoxic antigens in H-RS cells may represent a poor prognostic factor in CHL, even if their expression is not regarded as lineage specific. Examination of T-cell and/or cytotoxic molecules phenotype in CHL patients is recommended as a routine pathologic practice.

Entities:  

Mesh:

Year:  2006        PMID: 16954517     DOI: 10.1200/JCO.2006.06.5342

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  27 in total

Review 1.  Diagnosis of Hodgkin lymphoma in the modern era.

Authors:  Hao-Wei Wang; Jayalakshmi P Balakrishna; Stefania Pittaluga; Elaine S Jaffe
Journal:  Br J Haematol       Date:  2018-11-08       Impact factor: 6.998

2.  Prognostic analysis and a new risk model for Hodgkin lymphoma in Japan.

Authors:  Kuniaki Itoh; Tomohiro Kinoshita; Takashi Watanabe; Kenichi Yoshimura; Rumiko Okamoto; Takaaki Chou; Michinori Ogura; Masami Hirano; Hideki Asaoku; Mitsutoshi Kurosawa; Yoshiharu Maeda; Ken Omachi; Yukiyoshi Moriuchi; Masaharu Kasai; Kazunori Ohnishi; Nobuyuki Takayama; Yasuo Morishima; Kensei Tobinai; Harumi Kaba; Seiichiro Yamamoto; Haruhiko Fukuda; Masahiro Kikuchi; Tadashi Yoshino; Yoshihiro Matsuno; Tomomitsu Hotta; Masanori Shimoyama
Journal:  Int J Hematol       Date:  2010-03-03       Impact factor: 2.490

3.  Linkage of expression of chemokine receptors (CXCR3 and CCR4) and cytotoxic molecules in peripheral T cell lymphoma, not otherwise specified and ALK-negative anaplastic large cell lymphoma.

Authors:  Naoko Asano; Ritsuro Suzuki; Koichi Ohshima; Yoshitoyo Kagami; Fumihiro Ishida; Tadashi Yoshino; Hiroshi Ogawa; Yasuo Morishima; Shigeo Nakamura
Journal:  Int J Hematol       Date:  2010-03-09       Impact factor: 2.490

Review 4.  Insights into the molecular roles of heparan sulfate proteoglycans (HSPGs-syndecans) in autocrine and paracrine growth factor signaling in the pathogenesis of Hodgkin's lymphoma.

Authors:  Rajendra Gharbaran
Journal:  Tumour Biol       Date:  2016-06-18

Review 5.  Epstein-Barr virus-related lymphoproliferative disorders.

Authors:  Nina D Wagner-Johnston; Richard F Ambinder
Journal:  Curr Hematol Malig Rep       Date:  2007-10       Impact factor: 3.952

6.  Cytotoxic molecule-positive classical Hodgkin's lymphoma: a clinicopathological comparison with cytotoxic molecule-positive peripheral T-cell lymphoma of not otherwise specified type.

Authors:  Naoko Asano; Tomohiro Kinoshita; Jun-Ichi Tamaru; Koichi Ohshima; Tadashi Yoshino; Nozomi Niitsu; Norifumi Tsukamoto; Kaoru Hirabayashi; Koji Izutsu; Masafumi Taniwaki; Yasuo Morishima; Shigeo Nakamura
Journal:  Haematologica       Date:  2011-08-22       Impact factor: 9.941

7.  CD137 is expressed in follicular dendritic cell tumors and in classical Hodgkin and T-cell lymphomas: diagnostic and therapeutic implications.

Authors:  Matthew W Anderson; Shuchun Zhao; Aharon G Freud; Debra K Czerwinski; Holbrook Kohrt; Ash A Alizadeh; Roch Houot; Denize Azambuja; Irene Biasoli; José Carlos Morais; Nelson Spector; Hernan F Molina-Kirsch; Roger A Warnke; Ronald Levy; Yasodha Natkunam
Journal:  Am J Pathol       Date:  2012-09       Impact factor: 4.307

8.  PAX5-positive T-cell anaplastic large cell lymphomas associated with extra copies of the PAX5 gene locus.

Authors:  Andrew L Feldman; Mark E Law; David J Inwards; Ahmet Dogan; Rebecca F McClure; William R Macon
Journal:  Mod Pathol       Date:  2010-01-29       Impact factor: 7.842

9.  Peripheral T-cell lymphomas of follicular T-helper cell derivation with Hodgkin/Reed-Sternberg cells of B-cell lineage: both EBV-positive and EBV-negative variants exist.

Authors:  Alina Nicolae; Stefania Pittaluga; Girish Venkataraman; Anahi Vijnovich-Baron; Liqiang Xi; Mark Raffeld; Elaine S Jaffe
Journal:  Am J Surg Pathol       Date:  2013-06       Impact factor: 6.394

10.  Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors.

Authors:  Katy Milne; Martin Köbel; Steven E Kalloger; Rebecca O Barnes; Dongxia Gao; C Blake Gilks; Peter H Watson; Brad H Nelson
Journal:  PLoS One       Date:  2009-07-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.